Myriad Genetics to Present Five Clinical Studies at 2014 ASCO GU Cancer Symposium

January 23, 2014 at 7:00 AM EST

SALT LAKE CITY, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from four studies in prostate cancer with Prolaris® and one study in renal cancer will be presented at the 2014 ASCO Genitourinary Cancers Symposium, which will be held Jan. 30-Feb. 1, 2014 in San Francisco, Calif. Prolaris is a prognostic test that accurately predicts cancer-specific death and metastases based on an analysis of 46 cell cycle progression genes. The Prolaris score is a stronger predictor of prostate cancer death and recurrence than clinical parameters such as Gleason score and PSA and has been validated in 11 clinical studies with more than 5,000 patients. The Company also will present data from a study with an investigational prognostic test in development for renal cell carcinoma. 

Title:  Prolaris CCP score stratifies risk for prostate cancer patients at biopsy: initial commercial results.
Presenter:  David Crawford
Date:  Thursday, Jan. 30, 11:30 a.m. to 1:00 p.m. and 5:15 to 6:45 p.m. PST(Poster Session A)
Title:  Cell cycle progression score significantly modifies treatment decisions in prostate cancer: Results of an ongoing registry trial.
Presenter:  Ashok Kar
Date:  Friday, Jan. 31, 12:00 to 1:30 p.m. and 5:45 to 7:15 p.m. PST (Poster Session B)
Title:  Prognostic utility of the cell cycle progression score generated from needle biopsy in men treated with prostatectomy.
Presenter:  Jay Bishoff
Date:  Thursday, Jan. 30, 11:30 a.m. to 1:00 p.m. and 5:15 to 6:45 p.m. PST(Poster Session A)
Title:  Cell cycle progression score to predict metastatic progression of clear cell renal carcinoma after resection.
Presenter:  Erik Askeland
Date:  Saturday, Feb. 1, 6:45 to 7:55 a.m. and 11:30 a.m. to 12:30 p.m. PST (Poster Session C)

About Prolaris®

Prolaris is a novel prognostic test developed by Myriad Genetics that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of multiple genes related to the progression of tumor cell division. Prolaris can identify low-risk patients who may be candidates for surveillance as well as patients who may be potentially at higher risk and would benefit from closer monitoring or additional therapy. Prolaris has been proven to predict prostate cancer-specific disease progression in five published clinical trials. For more information visit: and

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the presentation of Prolaris clinical study data at the 2014 ASCO Genitourinary Cancers Symposium; data showing that physicians would change their treatment plan of patients with prostate cancer based on Prolaris test results; the effectiveness of Prolaris testing to accurately predict cancer-specific disease progression and mortality when combined with clinical parameters such as Gleason score and PSA; and the Company's strategic directives under the caption "About Myriad Genetics". These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and companion diagnostic services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

CONTACT: Media Contact:

         Ron Rogers

         (801) 584-3065

         Investor Contact:

         Scott Gleason

         (801) 584-1143

Source: Myriad Genetics, Inc.

News Provided by Acquire Media